Investigators are also exploring the potential of combination therapies using A2A receptor antagonists and other checkpoint inhibitors such as anti-PD-1/PD-L1-based therapies, since adenosine receptor 2A blockade can enhance the effectiveness of anti-PD-1/PD-L1-based therapies by enhancing the anti-tumor T cell response [9,10]. The gene discussed is PDCD1; the disease is neoplasm.